调强放疗联合或不联合化疗治疗中危鼻咽癌的疗效与安全性
本研究配对比较124例II期及T3N0M0鼻咽癌患者接受单纯调强放疗(IMRT)或IMRT联合化疗的生存与毒性,两组5年OS、DFS、LRRFS、DMFS均无显著差异,但联合化疗组3级急性黏膜炎、白细胞减少/中性粒细胞减少及恶心呕吐发生率显著更高。
要点
- 中危(II期及T3N0M0)鼻咽癌IMRT联合化疗未显示生存获益。
- 联合化疗组3级急性黏膜炎、白细胞减少/中性粒细胞减少及恶心呕吐显著增加。
- 5年OS、DFS、LRRFS、DMFS两组间均无统计学差异。
核心结论
- 对于中危(II期和T3N0M0)鼻咽癌患者,IMRT联合化疗较单纯IMRT未提供生存获益,且3级急性毒性更常见。
研究设计与样本
- 124例II期和T3N0M0鼻咽癌患者按1:1配对匹配分为单纯IMRT组和IMRT联合化疗组,比较生存结局与治疗相关3-4级急性毒性事件。
主要发现
- 5年OS为91.9% vs. 90.3%(P=0.727),DFS为87.1% vs. 88.7%(P=0.821),LRRFS为96.8% vs. 95.2%(P=0.646),DMFS为91.9% vs. 91.5%(P=0.955)。
- 3级急性黏膜炎发生率为15% vs. 5%(P=0.004),白细胞减少/中性粒细胞减少为8% vs. 1%(P<0.015),恶心/呕吐为22% vs. 3%(P<0.001)。
关键数值与推荐
- 5年OS:91.9%(单纯IMRT)vs. 90.3%(IMRT联合化疗),P=0.727。
- 5年DFS:87.1% vs. 88.7%,P=0.821。
- 5年LRRFS:96.8% vs. 95.2%,P=0.646。
- 5年DMFS:91.9% vs. 91.5%,P=0.955。
- 3级急性毒性:黏膜炎15% vs. 5%(P=0.004);白细胞减少/中性粒细胞减少8% vs. 1%(P<0.015);恶心/呕吐22% vs. 3%(P<0.001)。
临床怎么用
- 对于II期和T3N0M0中危鼻咽癌,可考虑单纯IMRT以避免化疗相关3级急性毒性,但需结合个体情况权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study directs to evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) alone versus IMRT plus chemotherapy in intermediate-risk NPC (stage II and T3N0M0). METHODS: A total of 124 patients with stage II and T3N0M0 NPC were pair-matched (1:1 ratio) to form two groups: an IMRT-alone group and an IMRT/chemotherapy group. Survival outcomes (overall survival [OS], disease-free survival [DFS], locoregional relapse-free survival [LRRFS], distant metastasis-free survival [DMFS]) and treatment-related grade 3-4 acute toxicity events were compared between the groups. RESULTS: Survival outcomes for patients with stage II and T3N0M0 NPC were quiet comparable between patients treated with IMRT alone versus patients treated with IMRT/chemotherapy: 5-year OS was 91.9% vs. 90.3%, respectively (P = 0.727); DFS was 87.1% vs. 88.7%, respectively (P = 0.821); LRFFS was 96.8% vs. 95.2%, respectively (P = 0.646), and DMFS was 91.9% vs. 91.5%, respectively (P = 0.955). Grade 3 acute toxicities were significantly higher with IMRT/chemotherapy than with IMRT alone: mucositis, 15% vs. 5% (P = 0.004); leukopenia/neutropenia, 8% vs. 1% (P < 0.015); and nausea/vomiting, 22% vs. 3% (P < 0.001). CONCLUSION: For intermediate-risk (stage II and T3N0M0) NPC patients, the addition of chemotherapy to IMRT does not appear to provide any survival benefit. Moreover, grade 3 acute toxicities are also more common in patients receiving IMRT plus chemotherapy.
引用
- Aftab O, Liao S, Zhang R, et al. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma. Radiat Oncol. 2020. PMID: 32178698. doi:10.1186/s13014-020-01508-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。